GUIZHOU BAILING GROUP PHARMACEUTICAL

guizhou-bailing-group-pharmaceutical-logo

Guizhou Bailing Group Pharmaceutical is a pharmaceutical company.

#SimilarOrganizations #Website #More

GUIZHOU BAILING GROUP PHARMACEUTICAL

Social Links:

Industry:
Health Care Pharmaceutical

Founded:
1999-01-01

Address:
Anshun, Guizhou, China

Country:
China

Website Url:
http://www.gzbl.com

Total Employee:
5001+

Status:
Active

Contact:
86-851-3341-5126

Email Addresses:
[email protected]

Technology used in webpage:
SSL By Default Mobile Non Scaleable Content Apple Mobile Web App Capable IIS DigiCert SSL Apple Mobile Web App Status Bar Style Java EE IIS 8 Encryption Everywhere Alibaba


Similar Organizations

taiko-pharmaceutical-logo

Taiko Pharmaceutical

Taiko Pharmaceutical is a pharmaceutical company.

Stock Details


Company's stock symbol is SZSE:002424

Official Site Inspections

http://www.gzbl.com

  • Host name: 120.77.211.17
  • IP address: 120.77.211.17
  • Location: Hangzhou China
  • Latitude: 30.294
  • Longitude: 120.1619
  • Timezone: Asia/Shanghai

Loading ...

More informations about "Guizhou Bailing Group Pharmaceutical"

Guizhou Bailing Group Pharmaceutical - Crunchbase

Guizhou Bailing Group Pharmaceutical is in the drug industry. They produce and sell Miao medicine. Their products include non-prescription drugs, prescription drugs, big health …See details»

Guizhou Bailing Group Pharmaceutical Company Description

Oct 31, 2024 Company profile for Guizhou Bailing Group Pharmaceutical Co., Ltd. (SHE: 002424) with a description, list of executives, contact details and other key facts.See details»

Guizhou Bailing Group Pharmaceutical Co., Ltd.

了解Guizhou Bailing Group Pharmaceutical Co., Ltd. (贵州百灵企业集团制药股份有限公司)公司的药物管线,治疗领域,技术平台,以及它的17项临床试验, 64篇新闻和5篇文献,疾病领域:神 …See details»

贵州百灵企业集团制药股份有限公司 - m.gzbl.com

贵州百灵企业集团制药股份有限公司(以下简称“贵州百灵”)是一家从事苗药研发、生产、销售于一体的医药上市公司,注册资本14.112亿元,总资产70.59亿元,员工5961人。See details»

Guizhou Bailing Group Pharmaceutical Company - PitchBook

Sep 24, 2015 Information on stock, financials, earnings, subsidiaries, investors, and executives for Guizhou Bailing Group Pharmaceutical Company. Use the PitchBook Platform to explore …See details»

Guizhou Bailing Group - Craft

Oct 21, 2024 Guizhou Bailing Group ¥4.21 b in annual revenue in FY 2023. See insights on Guizhou Bailing Group including office locations, competitors, revenue, financials, executives, …See details»

Guizhou Bailing Group Pharmaceutical - Business Information

View Guizhou Bailing Group Pharmaceutical (www.gzbl.com) location in Guizhou, China , revenue, industry and description. Find related and similar companies as well as employees …See details»

贵州百灵企业集团制药股份有限公司_www.gzbl.com

贵州百灵企业集团制药股份有限公司:贵州百灵是一家从事苗药研发、生产、销售于一体的医药上市公司。2010年6月,公司在深圳证券交易所成功上市(股票代码:sz002424)。经过多年的 …See details»

Guizhou Bailing Group Pharmaceutical Co., Ltd. - Drug pipelines ...

Explore Guizhou Bailing Group Pharmaceutical Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 17 clinical trials, and 5 literature, Disease ...See details»

贵州百灵企业集团制药股份有限公司 - gzbl.com

姓名:李听. 邮箱:[email protected]. 电话:15708295307. 留言内容:想了解一下贵公司的招聘信息. 发布日期:2022-03-14 17:19:30See details»

ST百灵(002424)公司资料简介-中商产业研究院数据库-中商情报网

公司名称: 贵州百灵企业集团制药股份有限公司: 英文名称: Guizhou Bailing Group Pharmaceutical Co.,Ltd. 曾 用 名: 贵州百灵See details»

Organization: Guizhou Bailing Group Pharmaceutical - Cbonds.com

Guizhou Bailing Group Pharmaceutical. Information about the issuer. News and credit ratings. . Tables with accounting and financial reporting.See details»

贵州百灵企业集团制药股份有限公司 - m.gzbl.com

一篇文章带你了解贵州百灵药材基地. 为充分发挥国家级龙头企业的优势,以建立优质药源供应基地为目的,贵州百灵实施 ...See details»

贵州百灵:坚守品质安全底线 创新推动中医药高质量发展--贵州百 …

贵州百灵:坚守品质安全底线 创新推动中医药高质量发展, 贵州百灵企业集团制药股份有限公司See details»

贵州百灵企业集团制药股份有限公司 - m.gzbl.com

贵州百灵与楚济堂医药集团战略对接会顺利召开See details»

贵州百灵企业集团制药股份有限公司 - gzbl.com

©2021 贵州百灵企业集团制药股份有限公司 版权所有 . 互联网药品信息服务资格证书编号:(黔)-非经营性—2020-0045See details»

贵州百灵:2022年上半年营利双增,扩能技改项目竣工在即--贵州 …

贵州百灵:2022年上半年营利双增,扩能技改项目竣工在即, 贵州百灵企业集团制药股份有限公司See details»

贵州百灵参股公司赜灵生物“注射用甲磺酸普依司他”治疗复发或难 …

8月31日晚间,贵州百灵发布参股子公司在研项目进展公告,赜灵生物近日收到《四川大学华西医院临床试验伦理审查委员会批件》,同意公司开展“注射用甲磺酸普依司他”治疗复发或难治弥 …See details»

贵州百灵独家苗药“双羊喉痹通颗粒”获批临床 拟扩大适用人群范围

本次申请扩大“双羊喉痹通颗粒”适用人群范围,如获得批准,将进一步增强该品种的市场竞争力,为公司盈利能力提升产生 ...See details»

linkstock.net © 2022. All rights reserved